Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models
作者:Alessia Romussi、Anna Cappa、Paola Vianello、Silvia Brambillasca、Maria Rosaria Cera、Roberto Dal Zuffo、Giovanni Fagà、Raimondo Fattori、Loris Moretti、Paolo Trifirò、Manuela Villa、Stefania Vultaggio、Valentina Cecatiello、Sebastiano Pasqualato、Giulio Dondio、Chi Wai Eric So、Saverio Minucci、Luca Sartori、Mario Varasi、Ciro Mercurio
DOI:10.1021/acsmedchemlett.9b00604
日期:2020.5.14
methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery
赖氨酸特异性脱甲基酶1(LSD1或KDM1A)是一种FAD依赖性酶,通过分别调节组蛋白H3赖氨酸K4和K9的甲基化状态,充当转录共抑制因子或共激活因子。KDM1A代表了一种有吸引力的癌症治疗靶标。过去,抑制KDM1A的主要药物化学策略是基于对与酶催化位点内FAD辅助因子不可逆结合的配体的优化,我们和其他人也已经确定了可逆抑制剂。在本文中,我们报告了5-咪唑基噻吩并[3,2-b]吡咯的发现,5-咪唑基噻吩并[3,2-b]吡咯类具有皮摩尔抑制潜能,在小鼠白血病模型中口服后对细胞有效且有效。